Encorafenib companion diagnostic - Novartis
Latest Information Update: 04 Nov 2017
At a glance
- Originator Novartis
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Combination therapy, Diagnosis) in European Union
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Combination therapy, Diagnosis) in USA
- 08 Nov 2012 Clinical trials in Malignant melanoma (combination therapy, diagnosis) in European Union (unspecified route)